PATRIN PHARMA, Inc. – Trademark Portfolio

Entity Type: 03

PATRIN PHARMA, Inc. holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 7 filings in this category. Currently, 7 trademarks are registered. Notable registered marks include FLAC, HYSEPT, MX-SOL, H-CHLOR, and CALCIDOL. The owner is based in Skokie, IL.

I.P. Group

7817 Babb Avenue

Skokie, IL 600773636

8 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

SOLUVITA
SOLUVITA
Registered 2018
FLAC
FLAC
Registered 2016
MX-SOL
MX-SOL
Registered 2014
H-CHLOR
H-CHLOR
Registered 2012
HYSEPT
HYSEPT
Registered 2012
HY-CHLO
HY-CHLO
Abandoned 2011
CALCIDOL
CALCIDOL
Registered 2007

Trademark Classifications

PATRIN PHARMA, Inc.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (7 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does PATRIN PHARMA, Inc. have?

PATRIN PHARMA, Inc. has 8 U.S. trademarks filed with the USPTO. Of these, 7 registered, 1 abandoned.

What trademark classes does PATRIN PHARMA, Inc. file in?

PATRIN PHARMA, Inc. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are PATRIN PHARMA, Inc.'s most well-known trademarks?

PATRIN PHARMA, Inc.'s registered trademark portfolio includes well-known marks such as FLAC, HYSEPT, MX-SOL, H-CHLOR, and CALCIDOL. These are among 7 currently registered trademarks in the portfolio.

What is PATRIN PHARMA, Inc.'s trademark registration success rate?

PATRIN PHARMA, Inc. has a 88% trademark registration rate, with 7 out of 8 resolved applications resulting in successful registration. Currently, 0 applications are pending review.